Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: CRISPR Therapeutics vs. Editas Medicine

TheMotleyFool

0 0

Better Buy: CRISPR Therapeutics vs. Editas Medicine

Over the past year, shares of gene-editing companies Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) have shot up 129% and 212%, respectively. Their mouth-watering returns make the S&P 500's incredibly jump of 17% (during a fraught economic period and public health crisis, no less) look relatively puny.

As we enter the golden age of biotech, it could pay off to invest in the most innovative technologies and companies in the sector. Both firms are focusing their efforts on treating rare genetic disorders, and CRISPR is also specializing in immuno-oncology. Let's see if Editas or CRISPR Therapeutics has the better risk-reward potential.